Therapeutic Drug Monitoring of Infliximab in Iraqi Patients with Moderate to Severe Ulcerative Colitis
DOI:
https://doi.org/10.31351/vol34iss3pp90-99Keywords:
Antidrug antibodies, Inflammatory bowel disease, Infliximab, Therapeutic drug monitoring, Ulcerative colitisAbstract
The term "inflammatory bowel disease" refers to a group of gastrointestinal tract inflammatory disorders that are considered idiopathic, chronic, and relapsing. The two primary disorders that comprise inflammatory bowel disease are Crohn's disease and ulcerative colitis. Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases such ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and psoriasis. Therapeutic drug monitoring is a tool used in therapeutic decision-making that allows dosage modifications to be made in accordance with clinical and laboratory measures, usually blood concentrations of the drug, in order to achieve the drug exposure linked to the best response rate. The trough concentrations of infliximab at 3 to 7 μg/mL is most effective at inducing remission in patients with inflammatory bowel disease. The aims of the current study were to determine the achievement of trough level target, development of antidrug antibodies to Infliximab, assess response to therapy and to study trough level relation with different variables in patients with ulcerative colitis. The present study was cross-sectional conducted at ‟Gastroenterology and Hepatology Teaching Hospital/ Medical City / Baghdad / Iraq” during May 2022 to November 2022. Forty candidate patients with ulcerative colitis were included [Males =20 (50%), Females=20 (50%)] with median age [32.00 (28.50-40.75) years]. According to trough level, disease activity and development of antibodies, escalation of the dose were recommended for 10 patients (25%), switching therapy were recommended for 16 patients (40%), and continuation of the same dosage regimen were recommended for 14 patients (35%). In addition, results of current study showed that age, body mass index, and packed cell volume were significantly higher and erythrocyte sedimentation rate was significantly lower in in patients achieved target infliximab trough level compared to those not achieved. By using multivariate binary regression analysis only age and erythrocyte sedimentation rate can be used to predict the achievement of target trough level of infliximab. In conclusion, therapeutic drug monitoring of infliximab to determine the trough level and antidrug antibodies can explain the possible causes of non-responsiveness to this drug among ulcerative colitis patients with subsequent recommendations based on these findings.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Hussein M, Abdulrazzaq M. Evaluation of Anti-inflammatory Effects of Cinnamic Acid Against Dextran Sodium Sulfate Induced Ulcerative Colitis in Male Mice. Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512). 2023;32:33-40.
Nisreen Jumaah J, Dheyaa JK, Nawal MF, Hayder Adnan F. Assessment of health-related quality of life of Iraqi patients with inflammatory bowel disease. International Journal of Research in Pharmaceutical Sciences. 2018;9(3):714-20.
Mahmood HJ, Hashim AM, Salih AMM, Ibrahim RH, Al Mushhdany OI. Inflammatory Bowel Disease (IBD) in Mosul Hospital: A cross-Sectional Study-Analysis of Prevalence, Risk Factors, and Clinical Outcomes. Malaysian Journal of Medicine & Health Sciences. 2023;19(5).
Jebur N, Kadhim D, Alkhalidi N. Belief about Medications among Sample of Iraqi Patients with Inflammatory Bowel Disease. Iraqi Journal of Pharmaceutical Sciences ( P-ISSN: 1683 - 3597 , E-ISSN : 2521 - 3512). 2018;27:32-41.
Hussian S, Sabri W. Association of Infl ammatory Bowel Disease and Tumor Necrosis Factor-863 C/A Polymorphism in Iraq. International Journal Of Drug Delivery Technology. 2023;13:81-5.
Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Lee KC, Bookstaver PB. Pharmacotherapy Principles and Practice, Sixth Edition. Chapter 20, Inflammatory Bowel Disease. McGraw-Hill Education; 2022. p. 357-71.
Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine 21st edition. Chapter 326, Inflammatory Bowel Disease. McGraw Hill; 2022. p. 2469-89.
Wing EJ, Schiffman FJ. Cecil Essentials of Medicine. Chapter 38, Inflammatory Bowel Disease 10th edition.: Elsevier; 2021. p. 392-401.
Ad’hiah AH, Hessan EB, Shahab BA. Interleukin-1 single nucleotide polymorphisms as risk factors for susceptibility of inflammatory bowel disease: an Iraqi Arab population-based study. Alexandria Journal of Medicine. 2019;55(1):1-6.
Al-Rwi L, Alakori M, Abdulghafour K. Prevalence of Entamoeba Histolytica infection in patients with colitis (Ulcerative and Infective). Journal of the Faculty of Medicine-Baghdad. 2016;58:283-8.
Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol. 2015;21(1):21-46.
Jung SA. Differential diagnosis of inflammatory bowel disease: what is the role of colonoscopy? Clin Endosc. 2012;45(3):254-62.
de Lange T, Larsen S. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol. 2004;4:9.
Vultaggio A, Matucci A, Nencini F, Pratesi S, Maggi E. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. Internal and Emergency Medicine. 2012;7(2):77-9.
Fadhil H, Al-Jumaili AA, Al-Ani N. Cost-effectiveness Analysis of Reference Infliximab (Remicade) Compared to its Biosimilar (Remsima) in Iraqi Patients with Rheumatoid Arthritis (Conference Paper )#. Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512). 2023;31:100-10.
Jürgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9(5):421-7.e1.
Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol. 2016;9(4):513-26.
Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017;23(9):1510-5.
Younus M, A.Taher M, Askar B, Kurmanji J. Serum selenium correlations with C- reactive protein, calprotectin and disease activity in IBD patients treated with Infliximab. World Journal Of Pharmacy And Pharmaceutical Sciences. 2015;4:165-79.
Sobolewska A, Włodarczyk M, Stec-Michalska K, Fichna J, Wiśniewska-Jarosińska M. Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study. Dig Dis Sci. 2016;61(2):542-9.
Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, et al. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Dig Liver Dis. 2022;54(10):1367-73.
Cao Y, Dai Y, Zhang L, Wang D, Yu Q, Hu W, et al. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. Clin Biochem. 2022;100:35-41.
Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017;9:101-11.
Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017;153(3):827-34.
Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. Gastroenterology. 2015;148(7):1320-9.e3.
Martins CdA, Moss AC, Sobrado CW, Queiroz NSF. Practical Aspects of Proactive TDM for Anti-TNF Agents in IBD: Defining Time Points and Thresholds to Target. Crohn's & Colitis 360. 2019;1(3).
Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis. 2022;16(1):2-17.
Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis. 2020;14(1):4-22.
National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Ulcerative Colitis: Management in Adults, Children and Young People [Internet]. London: Royal College of Physicians (UK); National Clinical Guideline Centre.; 2013 [updated 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK247597/.
The Italian Group for study of Inflammatory Bowel Disease. Info MAYO | Partial [Internet]. 2023 [cited 5/8/2023]. Available from: https://www.igibdscores.it/en/info-mayo-partial.php.
Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR. Chapter 57, Acute Phase Reactants and the Concept of Inflammation. Kelley's Textbook of Rheumatology. 9th ed. Philadelphia, PA: Elsevier Saunders; 2013. p. 818-29.
Shikari® (Q-REMS) Infliximab biosimilar ELISA INF-FD-REMS [Internet]. Turkey: Matriks Biotek; 2023 [updated Jul 2023; cited 5/8/2023]. Available from: https://matriksbiotek.com/products/132/shikari-q-rems-infliximab-biosimilar-elisa.
Shikari® (S-AIR) Anti-Infliximab biosimilar ELISA w/confirmation INF-QNS-REMS [Internet]. Turkey: Matriks Biotek; 2023 [updated Jul 2023; cited 5/8/2023]. Available from: https://matriksbiotek.com/products/138/shikari-s-air-anti-infliximab-biosimilar-elisa-w-confirmation.
Human OSM(Oncostatin M) ELISA Kit (Catalog No: E-EL-H2247) [Internet]. China: Elabscience Biotechnology; 2023 [updated Apr 2023; cited 5/8/2023]. Available from: https://www.elabscience.com/p-human_osm_oncostatin_m_elisa_kit-19660.html.
Human CALP(Calprotectin) ELISA Kit (Catalog No: E-EL-H2357) [Internet]. China: Elabscience Biotechnology; 2023 [updated Apr 2023; cited 5/8/2023]. Available from: https://www.elabscience.com/p-human_calp_calprotectin_elisa_kit-19752.html.
Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65(2):249-55.
Kampa KC, Loures MR, Ivantes CAP, Petterle RR, Pedroso MLA. The Evaluation Of Infliximab Trough Level Favors Maintenance Therapy Of Patients With Inflammatory Bowel Disease. Arq Gastroenterol. 2023;60(1):48-56.
Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, et al. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease. Inflamm Bowel Dis. 2017;23(1):126-32.
Amiot A, Hulin A, Belhassan M, Andre C, Gagniere C, Le Baleur Y, et al. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clin Res Hepatol Gastroenterol. 2016;40(1):90-8.
Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16(4):378.
Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo MG, et al. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease. Clinics. 2019;74.
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426-31.
Croft A, Lord A, Radford-Smith G. Markers of Systemic Inflammation in Acute Attacks of Ulcerative Colitis: What Level of C-reactive Protein Constitutes Severe Colitis? Journal of Crohn's and Colitis. 2022;16(7):1089-96.
Griffey RT. What Is the Utility of ESR and CRP in the Evaluation of Acute IBD Presentations? In: Graham A, Carlberg DJ, editors. Gastrointestinal Emergencies: Evidence-Based Answers to Key Clinical Questions. Cham: Springer International Publishing; 2019. p. 315-6.
45. Choi S, Kang B, Choe Y. Serum Infliximab Cutoff Trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease. Gut and Liver. 2019;13.
Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, et al. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. Eur J Gastroenterol Hepatol. 2019;31(2):187-91.
Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, et al. Serum calprotectin as a biomarker for Crohn's disease. J Crohns Colitis. 2013;7(12):e678-83.
Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT, Nimmo ER, et al. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. Am J Gastroenterol. 2016;111(12):1796-805.
Mohamed GA, Mohamed HAE-L, Abo Halima AS, Elshaarawy MEA, Khedr A. Changes in Serum Oncostatin M Levels during Treatment of Inflammatory Bowel Disease. The Egyptian Journal of Hospital Medicine. 2022;89(2):7217-125.
Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, Cleynen I, et al. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021;27(10):1564-75.
Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther. 2020;52(2):284-91.
Minar P, Lehn C, Tsai YT, Jackson K, Rosen MJ, Denson LA. Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab. Crohns Colitis 360. 2019;1(3):otz026.
Kantasiripitak W, Verstockt B, Alsoud D, Lobatón T, Thomas D, Gils A, et al. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. British Journal of Clinical Pharmacology. 2021;87(10):3776-89.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
